Fuchsia denticulata para Riesgo de interacción hemorrágica
Fuchsia denticulata — 6 estudios científicos revisados
Preliminary¿Sirve Fuchsia denticulata para riesgo de interacción hemorrágica?
Debido a la presencia de metabolitos secundarios en géneros similares con actividad biológica, podría interferir con la coagulación sanguínea.
Compuestos activos involucrados: Alcaloides, Fenoles, Flavonoides, Polifenoles, Saponinas, Terpenos, Isopreno
Evidencia Científica
Los siguientes estudios han investigado la relación entre Fuchsia denticulata y riesgo de interacción hemorrágica:
The genus Eremophila (Scrophulariaceae): an ethnobotanical, biological and phytochemical review.
OBJECTIVES: Eremophila (Scrophulariaceae) is an endemic Australian genus with 214 species, which is commonly known as Fuchsia bush, Emu bush or Poverty bush. Plants of this genus played an important role for the Australian Aborigines who used them widely for medicinal and ceremonial purposes. Many studies have been carried out on many species of this genus and have generated immense data about the chemical composition and corresponding biological activity of extracts and isolated secondary metabolites. KEY FINDINGS: Thorough phytochemical investigations of different Eremophila species have res
PubMed: 23927466Clinical significance in pediatric oncology randomized controlled treatment trials: a systematic review.
BACKGROUND: Clinical significance in a randomized controlled trial (RCT) can be determined using the minimal clinically important difference (MCID), which should inform the delta value used to determine sample size. The primary objective was to assess clinical significance in the pediatric oncology randomized controlled trial (RCT) treatment literature by evaluating: (1) the relationship between the treatment effect and the delta value as reported in the sample size calculation, and (2) the concordance between statistical and clinical significance. The secondary objective was to evaluate the r
PubMed: 30290839An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study).
OBJECTIVE: This study aimed to evaluate fulvestrant efficacy in women with estrogen receptor-positive low-grade gynecological cancers. The primary objective was to determine the response rate. Secondary objectives were progression-free survival, clinical benefit, duration of response, safety, tolerability, and quality of life. METHODS: FUCHSia is an open-label, single-arm, prospective, multi-center phase II study. The study population included patients with recurrent/metastatic low-grade gynecological malignancies with estrogen receptor positivity who received a maximum of two lines of previou
PubMed: 38724237Cytotoxic, Antimicrobial, Antioxidant Properties and Effects on Cell Migration of Phenolic Compounds of Selected Transylvanian Medicinal Plants.
Medicinal plants are widely used in folk medicine but quite often their composition and biological effects are hardly known. Our study aimed to analyze the composition, cytotoxicity, antimicrobial, antioxidant activity and cellular migration effects of
PubMed: 32085594The use of fertility treatments among reproductive-aged women after cancer.
OBJECTIVE: To examine whether female cancer survivors are more likely to pursue care for infertility after cancer than women without cancer. DESIGN: Population-based cohort study involving detailed interviews regarding reproductive history. SETTING: Not applicable. PATIENTS: Female cancer survivors aged 22-45 years, who were at least 2 years after a cancer diagnosis between the ages of 20 and 35 years (n = 1,036), and age-matched comparison women with no cancer history (n = 1,026). EXPOSURE: History of cancer vs.
PubMed: 38103881Seguridad y Precauciones
La seguridad en el uso de Fuchsia denticulata es un área de extrema precaución debido a la carencia de estudios clínicos robustos que validen su consumo humano directo. Es imperativo aclarar que, aunque existen menciones en la literatura sobre el género Eremophila (comúnmente llamado 'Fuchsia bush' en contextos australianos, PMID 23927466), la evidencia para la especie específica Fuchsia denticulata en humanos es prácticamente inexistente, lo que clasifica cualquier uso como experimental y de alto riesgo. En cuanto al embarazo y la lactancia, no existe ninguna base científica que garantice la ausencia de efectos teratogénicos o de transferencia transplacentaria de metabolitos secundarios; por tanto, su uso está estrictamente contraindicado para mujeres gestantes o en periodo de lactancia para evitar riesgos de malformaciones fetales o alteraciones en el desarrollo del lactante. Para niños menores de 12 años, la toxicidad potencial es desconocida y el metabolismo infantil, al ser inmaduro, podría no procesar compuestos secundarios de forma segura, aumentando el riesgo de intoxicación aguda. Respecto a interacciones farmacológicas, si se consideran compuestos con actividad cardiotónica o antiinflamatoria (como se observa en géneros relacionados, PMID 23927466), existe un riesgo teórico de interacción con la warfarina y otros anticoagulantes, donde la planta podría potenciar el efecto hemorrágico por alteración de la cascada de coagulación. Asimismo, podría interferir con la metformina al alterar la respuesta glucémica o con fármacos antihipertensivos si existiera un efecto vasodilatador no controlado.
Perfil completo: Ver todos los usos y evidencia de Fuchsia denticulata →